{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:57:50Z","timestamp":1790485070398,"version":"4.1.0"},"reference-count":43,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"INNOMED\/6\/I\/NCBR\/2014","award":["INNOMED\/6\/I\/NCBR\/2014"],"award-info":[{"award-number":["INNOMED\/6\/I\/NCBR\/2014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0456-1","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T01:12:27Z","timestamp":1543453947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-2972","authenticated-orcid":false,"given":"Jacek","family":"Mackiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Burzykowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"I\u017cycki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Mackiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,11,29]]},"reference":[{"issue":"1A","key":"456_CR1","first-page":"68","volume":"22","author":"J Mackiewicz","year":"2018","unstructured":"Mackiewicz J, Mackiewicz A. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemp Oncol (Pozn). 2018;22(1A):68\u201372.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"1","key":"456_CR2","first-page":"1","volume":"21","author":"J Mackiewicz","year":"2017","unstructured":"Mackiewicz J, Mackiewicz A. Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma. Contemp Oncol (Pozn). 2017;21(1):1\u20135.","journal-title":"Contemp Oncol (Pozn)"},{"key":"456_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.intimp.2017.03.015","volume":"46","author":"Q Wang","year":"2017","unstructured":"Wang Q, Wu X. Primary and acquired resistance to PD-1\/PD-L1 blockade in cancer treatment. Int Immunopharmacol. 2017;46:210\u20139. https:\/\/doi.org\/10.1016\/j.intimp.2017.03.015 .","journal-title":"Int Immunopharmacol"},{"key":"456_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","volume":"52","author":"JS O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1\/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71\u201381. https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.007 .","journal-title":"Cancer Treat Rev."},{"key":"456_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.21037\/atm.2017.06.47","volume":"5","author":"N Karachaliou","year":"2017","unstructured":"Karachaliou N, Gonzalez-Cao M, Sosa A, Berenguer J, Bracht JWP, Ito M, Rosell R. The combination of checkpoint immunotherapy and targeted therapy in cancer. Ann Transl Med. 2017;5:19\u2013388.","journal-title":"Ann Transl Med"},{"issue":"43","key":"456_CR6","doi-asserted-by":"publisher","first-page":"75675","DOI":"10.18632\/oncotarget.18523","volume":"8","author":"HR Keller","year":"2017","unstructured":"Keller HR, Zhang X, Li L, Schaider H, Wells JW. Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. Oncotarget. 2017;8(43):75675\u201386. https:\/\/doi.org\/10.18632\/oncotarget.18523 .","journal-title":"Oncotarget"},{"key":"456_CR7","first-page":"610","volume":"9","author":"JM Grenier","year":"2018","unstructured":"Grenier JM, Yeung ST, Khanna KM. Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. FrontImmunol. 2018;9:610.","journal-title":"FrontImmunol."},{"issue":"2","key":"456_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.gene.2013.03.056","volume":"525","author":"A Koz\u0142owska","year":"2013","unstructured":"Koz\u0142owska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines. Gene. 2013;525(2):200\u20137. https:\/\/doi.org\/10.1016\/j.gene.2013.03.056 .","journal-title":"Gene"},{"key":"456_CR9","doi-asserted-by":"crossref","unstructured":"Kwiatkowska-Borowczyk E, Czerwi\u0144ska P, Mackiewicz J, et al. Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients. Oncoimmunology. 2018; doi.org\/10.1080\/2162402X.2018.1509821 .","DOI":"10.1080\/2162402X.2018.1509821"},{"issue":"6","key":"456_CR10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1517\/13543784.2012.684753","volume":"21","author":"A Mackiewicz","year":"2012","unstructured":"Mackiewicz A, Mackiewicz J, Wysocki PJ, et al. Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opin Investig Drugs. 2012;21(6):773\u201383. https:\/\/doi.org\/10.1517\/13543784.2012.684753 .","journal-title":"Expert Opin Investig Drugs."},{"issue":"19","key":"456_CR11","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016;375(19):1845\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1611299 .","journal-title":"N Engl J Med"},{"key":"456_CR12","unstructured":"NIH; U.S. National Library of Medicine, http:\/\/clinicaltrials.gov [NCT03068455] (assessed 30.07.2018)."},{"issue":"9","key":"456_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","volume":"154","author":"LL Wang","year":"2018","unstructured":"Wang LL, Patel G, Chiesa-Fuxench ZC, et al. Timing of onset of adverse cutaneous reactions associated with programed cell death protein 1 inhibitory therapy. JAMA Dermatol. 2018;154(9):1057\u201361. https:\/\/doi.org\/10.1001\/jamadermatol.2018.1912 .","journal-title":"JAMA Dermatol"},{"issue":"1-3","key":"456_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejphar.2009.09.069","volume":"625","author":"Jacek Mackiewicz","year":"2009","unstructured":"Mackiewicz A. Vaccine compositions. EP 2252322 (2009), DOI: https:\/\/doi.org\/10.1016\/j.ejphar.2009.09.069 .","journal-title":"European Journal of Pharmacology"},{"issue":"8","key":"456_CR15","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1016\/j.transproceed.2010.07.028","volume":"42","author":"J. Mackiewicz","year":"2010","unstructured":"Mackiewicz A, Wysocki PJ, Suchorska W. Vaccine compositions. US2011002898; 2010. Available from: www.freepatentsonline.com\/y2011\/0002898.html , DOI: https:\/\/doi.org\/10.1016\/j.transproceed.2010.07.028","journal-title":"Transplantation Proceedings"},{"key":"456_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cellsig.2013.01.007","volume":"4","author":"SY Kim","year":"2013","unstructured":"Kim SY, Kang JW, Song X, et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal. 2013;4:961\u20139.","journal-title":"Cell Signal."},{"key":"456_CR17","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4049\/jimmunol.149.6.2021","volume":"149","author":"A Mackiewicz","year":"1992","unstructured":"Mackiewicz A, Schooltink H, Heinrich P, Rose-John S. Soluble human IL-6-receptor\/IL-6 up-regulates expression of acute phase proteins. J. Immunol. 1992;149:2021\u20137.","journal-title":"J. Immunol."},{"key":"456_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/nbt0297-142","volume":"15","author":"M Fisher","year":"1997","unstructured":"Fisher M, Goldschmitt J, Peschel C, et al. A bioactive designer cytokine for human hematopoetic cell expansion. Nat Biotechnol. 1997;15:142\u20135. https:\/\/doi.org\/10.1038\/nbt0297-142 .","journal-title":"Nat Biotechnol"},{"key":"456_CR19","first-page":"139","volume":"14","author":"D Izycki","year":"2005","unstructured":"Izycki D, Nawrocki S, Filas V, et al. IL-6 and soluble IL-6 receptor gene modified tumor vaccine induces more efficient anti-melanoma immune responses and polarizes response towards Th1 type. Pol J Environ Stud. 2005;14:139\u201359.","journal-title":"Pol J Environ Stud"},{"key":"456_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/cgt.2010.2","volume":"17","author":"PJ Wysocki","year":"2010","unstructured":"Wysocki PJ, Kazimierczak U, Suchorska W, et al. Gene-modified tumor vaccine secreting Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gen Ther. 2010;17:465\u201375. https:\/\/doi.org\/10.1038\/cgt.2010.2 .","journal-title":"Cancer Gen Ther"},{"issue":"1\u20133","key":"456_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejphar.2009.09.069","volume":"625","author":"J Mackiewicz","year":"2009","unstructured":"Mackiewicz J, Mackiewicz A. Design of clinical trials for therapeutic cancer vaccine development. Eur J Pharmacol. 2009;625(1\u20133):84\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"456_CR22","first-page":"187","volume":"19","author":"J Mackiewicz","year":"2015","unstructured":"Mackiewicz J, Kotlarski M, Dondajewska E, Nowicka-Kotlarska A, Krokowicz \u0141, Kazimierczak U. Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines combined with low dose cyclophosphamide in an orthotopic murine prostate cancer model. Contemp Oncol. 2015;19(3):187\u201394.","journal-title":"Contemp Oncol"},{"issue":"6","key":"456_CR23","first-page":"3275","volume":"35","author":"J Mackiewicz","year":"2015","unstructured":"Mackiewicz J, Kazimierczak U, Kotlarski M, Dondajewska E, Koz\u0142owska A, Kwiatkowska E, Nowicka-Kotlarska A, Dams-Koz\u0142owska H, Wysocki PJ, Mackiewicz A. Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model. Anticancer Res. 2015;35(6):3275\u201388.","journal-title":"Anticancer Res."},{"key":"456_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/CMR.0000000000000144","volume":"25","author":"L Yue","year":"2015","unstructured":"Yue L, Huang Z-M, Fong S, Leong S, Jakowatz JG, Charruyer-Reinwald A, Wei M, Ghadially R. Targeting ALDH1 to decrease tumorigenicity, growth, and metastases of human melanoma. Melanoma Res. 2015;25:138\u201348. https:\/\/doi.org\/10.1097\/CMR.0000000000000144 .","journal-title":"Melanoma Res."},{"key":"456_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/MD.0000000000000853","volume":"94","author":"J Mackiewicz","year":"2015","unstructured":"Mackiewicz J, Karczewska-Dzionk A, Laciak M, et al. Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma. Medicine (Baltimore). 2015;94:21.","journal-title":"Medicine (Baltimore)"},{"key":"456_CR26","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1073\/pnas.95.17.10067","volume":"95","author":"AA Hurwitz","year":"1998","unstructured":"Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA. 1998;95:10067\u201310,071.","journal-title":"Proc Natl Acad Sci USA"},{"key":"456_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"AA Hurwitz","year":"1999","unstructured":"Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355\u201366.","journal-title":"J Exp Med"},{"key":"456_CR28","first-page":"2444","volume":"60","author":"AA Hurwitz","year":"2000","unstructured":"Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000;60:2444\u20138.","journal-title":"Cancer Res"},{"key":"456_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1479-5876-11-89","volume":"11","author":"S Wada","year":"2013","unstructured":"Wada S, Jackson CM, Yoshimura K, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89. https:\/\/doi.org\/10.1186\/1479-5876-11-89 .","journal-title":"J Transl Med"},{"key":"456_CR30","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107:4275\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"456_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.canlet.2005.02.005","volume":"231","author":"O Met","year":"2006","unstructured":"Met O, Wang M, Pedersen AE, Nissen MH, Buus S, Claesson MH. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett. 2006;231:247\u201356. https:\/\/doi.org\/10.1016\/j.canlet.2005.02.005 .","journal-title":"Cancer Lett"},{"key":"456_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.canlet.2005.04.012","volume":"235","author":"AE Pedersen","year":"2006","unstructured":"Pedersen AE, Buus S, Claesson MH. Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer Lett. 2006;235:229\u201338. https:\/\/doi.org\/10.1016\/j.canlet.2005.04.012 .","journal-title":"Cancer Lett"},{"key":"456_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/2162402X.2015.1043504","volume":"4","author":"HI Cho","year":"2015","unstructured":"Cho HI, Jung SH, Sohn HJ, Celis E, Kim TG. An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects. Oncoimmunology. 2015;4:11\u2013e1043504.","journal-title":"Oncoimmunology"},{"key":"456_CR34","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.1158\/0008-5472.CAN-13-1550","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013;73:6900\u201312. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1550 .","journal-title":"Cancer Res"},{"key":"456_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.canlet.2013.03.010","volume":"336","author":"Y Ge","year":"2013","unstructured":"Ge Y, Xi H, Ju S, Zhang X. Blockade of PD-1\/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett. 2013;336:253\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2013.03.010 .","journal-title":"Cancer Lett"},{"key":"456_CR36","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1158\/0008-5472.CAN-13-2685","volume":"74","author":"J Fu","year":"2014","unstructured":"Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res. 2014;74:4042\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2685 .","journal-title":"Cancer Res"},{"issue":"19","key":"456_CR37","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-09-1254","volume":"15","author":"A Ribas","year":"2009","unstructured":"Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009;15(19):6267\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1254 .","journal-title":"Clin Cancer Res"},{"key":"456_CR38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","volume":"13","author":"AJ van den Eertwegh","year":"2012","unstructured":"van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(12)70007-4 .","journal-title":"Lancet Oncol"},{"key":"456_CR39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","volume":"36","author":"DT Le","year":"2013","unstructured":"Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36:382\u20139. https:\/\/doi.org\/10.1097\/CJI.0b013e31829fb7a2 .","journal-title":"J Immunother"},{"key":"456_CR40","doi-asserted-by":"crossref","unstructured":"Kudchadkar RR, Gallenstein D, Martinez AJ, et al. Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma. J Clin Oncol. 2012;30(suppl 15):8582.","DOI":"10.1200\/jco.2012.30.15_suppl.8582"},{"issue":"4","key":"456_CR41","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","volume":"21","author":"GT Gibney","year":"2015","unstructured":"Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2468 .","journal-title":"Clin Cancer Res"},{"issue":"13","key":"456_CR42","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu W, Kefford R, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology. 2016;34(13):1510\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.64.0391 .","journal-title":"Journal of Clinical Oncology"},{"key":"456_CR43","volume-title":"Efficacy and safety of nivolumab in patients with advanced melanoma treated beyond progression in Check-Mate 066\/067","author":"GV Long","year":"2015","unstructured":"Long GV, Weber JS, Larkin J, et al. Efficacy and safety of nivolumab in patients with advanced melanoma treated beyond progression in Check-Mate 066\/067. San Francisco: Presented at Society of Melanoma Research (SMR) International Congress; 2015."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0456-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0456-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0456-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T17:51:32Z","timestamp":1694109092000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0456-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0456-1","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,29]]},"assertion":[{"value":"10 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human investigations were performed after approval by an institutional review board or ethics committee in accordance with an assurance filed with and approved by the Polish Ministry of Health. Written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J. Mackiewicz \u2013 advisory board Bristol-Myers Squibb; speakers\u2019 bureau \u2013 Bristol-Myers Squibb; GlaxoSmithKline, Roche, MSD, Novartis; travel reimbursement: Bristol-Myers Squibb, GlaxoSmithKline, Roche, MSD, Novartis.A. Mackiewicz \u2013 is a shareholder of BioContract Sp. z o.o. (contract vaccine manufacturing company); travel reimbursements: Roche, Bristol-Myers Squibb.T. Burzykowski - no competing interests reported.D. I\u017cycki - no competing interests reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"134"}}